ENDOSTART
15.7.2022 08:02:12 CEST | Business Wire | Press release
The growth of Italian medical device start-up Endostart continues with the appointment of Christopher Rowland, a global expert in the medical device industry, to Chairman of the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220714005706/en/
With over 30 years of experience in positions of increasing responsibility in sales, product development, marketing, business development, and CEO leadership in the US and abroad, Chris brings an unrivaled experience and competency in a wide variety of clinical and commercial medical devices verticals, including gastroenterology, cardiology, urology, radiology, and peripheral vascular specialties.
His professional experience includes 17 years with Boston Scientific, ending as the Global VP of Marketing for the Endoscopy Division; he also served as President of Given Imaging Inc. (acquired by Covidien/MDT) and President/CEO of Neotract Inc. (acquired by Teleflex). Chris is also currently the President and CEO of Tricol Biomedical, a leader in hemostasis technology.
In his new role, Chris will work with and coordinate the Board of Directors for Endostart.
“With his long history of leadership and his expertise in the digestive endoscopy industry, Chris is the ideal Chairman of the Board for Endostart,” said Alessandro Tozzi, CEO and founder of Endostart. “We are certain that Chris will be a driving force in our success.”
“I am excited to support the investors and the leadership team of this dynamic company. I believe Endostart is poised for significant growth reflecting demand for its innovative products to enhance endoscopic performance,” said Mr. Rowland. “I look forward to helping Endostart maximize shareholder value and realize its commercial potential.”
About Endorail™
The first product from Endostart is Endorail™, an innovative medical device aimed at facilitating completion of colonoscopy procedures using Magnetic Balloon Technology. This technology is designed to enhance endoscope performance and enable endoscopists to easily achieve quality standards. Endorail received a CE mark in 2019 and has been tested in a clinical setting. It is not yet cleared by the US Food and Drug Administration (FDA).
About Endostart
Founded in 2018, Endostart is focused on developing and manufacturing next-generation medical devices for gastrointestinal endoscopy. The company is ISO 13485 certified. It has an international board of directors and a strong medical advisory board. It recently announced a capital increase of €8.2M (USD $10M).
Website: www.endostart.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005706/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Even Realities Brings Classic Tortoiseshell Design to Smart Glasses with New Even G2 Brown 226.10.2026 15:00:00 CET | Press release
The new brown colorway pairs traditional eyewear craftsmanship with display-first technology, alongside Even G2 Clip (Polarized) and Even G2 Chain Even Realities, the company behind camera-free, display-first smart glasses, today introduced Brown 2, a new tortoiseshell-inspired colorway for Even G2, alongside two accessories: Even G2 Clip (Polarized) and the Even G2 Chain. Designed to bring the warmth and character of traditional tortoiseshell eyewear to smart glasses, Brown 2 features a newly developed material that carries its layered pattern throughout the frame rather than applying it as a surface finish. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026502782/en/ Even G2 Chain. Photo Credit: Even Realities Each frame is individually shaped, pressed, tumbled, and polished for 20 hours, creating subtle variations that make every pair unique. Brown 2 is also the lightest Even G2 design to date, while retaining the came
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 202626.10.2026 14:45:00 CET | Press release
INCB161734 (KRAS G12D inhibitor) and INCA338901 (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303 in colorectal cancer (CRC), respectivelyNew data evaluating INCB161734 in CRC highlight its clinical activity across KRAS G12D-mutated tumor types and support initiation of a Phase 3 study in second-line CRC planned for 2027INCB161734 and INCA33890 demonstrated manageable safety profiles in combination with standard-of-care (SoC) chemotherapiesNew collaborations with Bristol Myers Squibb and Synnovation in PDAC to evaluate INCB161734 in combination with navlimetostat, an MTA-cooperative PRMT5 inhibitor, and SNV1521, a PARP1 inhibitor, respectivelyThese results and additional updates will be presented at an analyst and investor event on Monday, October 26, 2026, from 7:30 – 9:00 p.m. CET (2:30 – 4:00 p.m. EDT) Incyte (Nasdaq:INCY) announced new results from its advancing on
Bending Spoons Completes the Acquisition of Miro26.10.2026 14:00:00 CET | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has completed the previously announced acquisition of Miro, the visual collaboration platform used by more than 250,000 organizations to brainstorm, plan, and build together. “Miro has built a strong business around a product that makes complex collaborative work feel simple,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro’s versatility has made it useful across a broad range of industries and workflows, while creating a robust foundation for further expansion. We believe there’s significant potential to build on these strengths. We look forward to drawing on Bending Spoons’ technologies and expertise to make Miro even more useful to customers and support its continued growth.” “Teams depend on Miro for innovating, alignment, coordination, and decisioning, and that need is only growing,“ said Andrey Khusid, CEO and co-founder of Miro. “In Bending Spoons, Miro has an owner who invests for the long term and cares deeply about product quali
Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 13:09:00 CET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach26.10.2026 13:00:00 CET | Press release
The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER cohort of 372 early-stage breast cancer patients with a median follow-up of 10.3 years Agendia, Inc., a leader in precision oncology for breast cancer, recently presented research introducing its investigational artificial intelligence (AI)-driven digital pathology approach for the MammaPrint®70-gene recurrence signature at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The podium presentation, delivered by co-founder and Chief Research Officer, Laura van ’t Veer, Ph.D., detailed the development and clinical validation of a deep learning pipeline that can infer MammaPrint (MP) risk categories directly from hematoxylin and eosin (H&E)-stained, whole-slide images (WSIs). The company also presented two additional posters highlighting data from the prospective, real-world FLEX Study (NCT03053193). “AI has been part of Agendia’s scientific fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom